Abacavir (Page 8 of 8)
Warning Card
Front
9202121/0918OS WARNING CARD
Abacavir Tablets USP
Patients taking abacavir tablets may have a serious allergic reaction (hypersensitivity reaction) that can cause death. If you get a symptom from 2 or more of the following groups while taking abacavir tablets, call your healthcare provider right away to find out if you should stop taking this medicine.
Back
Symptom(s) | |
Group 1 | Fever |
Group 2 | Rash |
Group 3 | Nausea, vomiting, diarrhea, or abdominal (stomach area) pain |
Group 4 | Generally ill feeling, extreme tiredness, or achiness |
Group 5 | Shortness of breath, cough, or sore throat |
Package/Label Display Panel – Carton – 300 mg
NDC 68084- 021 -21
Abacavir
Tablets USP
300 mg
30 Tablets (3 x 10) Rx Only
PHARMACIST: Dispense with the accompanying Medication
Guide and Warning Card to each patient.
Each Film-Coated Tablet Contains:
Abacavir sulfate USP equivalent to 300 mg of abacavir.
Usual Dosage: See package insert for full prescribing
information.
Store at 20° to 25°C (68° to 77°F); excursions permitted between
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Keep this and all drugs out of reach of children.
FOR YOUR PROTECTION: Do not use if blister is torn or broken.
The drug product contained in this package is from
NDC # 65862-073, Aurobindo Pharma USA, Inc.
Distributed by:
American Health Packaging
Columbus, Ohio 43217
002121 0202121/0918OS
Package/Label Display Panel – Blister – 300 mg
Abacavir Tablet USP
300 mg
ABACAVIR abacavir sulfate tablet, film coated | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
![]() | ||||||||||||||||||||||
|
Labeler — American Health Packaging (929561009) |
Establishment | |||
Name | Address | ID/FEI | Operations |
American Health Packaging | 929561009 | repack (68084-021) |
Revised: 11/2019 American Health Packaging
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.